Deleobuvir

Summary

Deleobuvir (CHEMBL2403318) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including chronic hepatitis c virus infection and kidney failure.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 10
• Chemistry: 653.6 Da · C34H33BrN6O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2403318
Name	Deleobuvir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	56948249
Molecular formula	C34H33BrN6O3
Molecular weight	653.6
InChIKey	BMAIGAHXAJEULY-UKTHLTGXSA-N

SMILES: CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7

IUPAC name: (E)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid

Also known as: BI 207127, BI-207127, Deleobuvir, DELEOBUVIR, [14C]-Deleobuvir, BI_207127

Parent form; salt/anhydrous children: CHEMBL3137315

Patent coverage: 74 distinct patent families (173 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 147 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
kidney failure	1	MONDO:0001106	HP:0000083

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	7
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01732796	PHASE3	COMPLETED	IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
NCT01858961	PHASE3	WITHDRAWN	Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
NCT01132313	PHASE2	COMPLETED	Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
NCT01525628	PHASE1	COMPLETED	Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
NCT01535638	PHASE1	COMPLETED	Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers
NCT01737996	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects
NCT01941615	PHASE1	TERMINATED	Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel
NCT01957657	PHASE1	TERMINATED	Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients
NCT01965431	PHASE1	COMPLETED	Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.
NCT01983566	PHASE1	TERMINATED	Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).